Our study advocates for the stratification of patients with acute myocardial infarction at risk of developing adverse events, based on the serum levels of two inflammatory biomarkers (I-CAM and MMP-9), regardless of presenting with STEMI or NSTEMI. Here, MMP9 is linked to acute myocardial infarction.